For adult patients with type 2 diabetes mellitus: Janumet is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. Janumet is indicated in combination with a sulphonylurea (i.e., triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea. Janumet is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e., a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPARγ agonist. Janumet is also indicated as add-on to insulin (i.e., triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control. The dose of antihyperglycaemic therapy with Janumet should be individualised on the basis of the patient's current regimen, effectiveness, and tolerability while not exceeding the maximum recommended daily dose of 100 mg sitagliptin. Adults with normal renal function (GFR ≥ 90 m L/min) For patients not adequately controlled on metformin alone, the usual starting dose should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) plus the dose of metformin already being taken. The dose should provide sitagliptin dosed as 50 mg twice daily (100 mg total daily dose) and a dose of metformin similar to the dose already being taken. Editors carefully fact-check all Drugwatch content for accuracy and quality. These drugs work by signaling the pancreas to create more insulin and decreasing the sugar made by the liver. Editors carefully fact-check all Drugwatch content for accuracy and quality. Janumet also comes in an extended release formula called Janumet XR. Januvia and Janumet are prescription drugs that belong to a group of Type 2 diabetes drugs called incretin therapies. Januvia (sitagliptin) is an oral Type 2 diabetes medication manufactured by Merck & Co. In 2007, the FDA approved a variation of Januvia called Janumet, which is a combination of sitagliptin and metformin. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts. Food and Drug Administration (FDA) approved the drug in 2006, and it is one of the most popular Type 2 diabetes drugs on the market. Both Januvia and Janumet belong to a class of drugs called dipeptidyl peptidase 4 (DPP-4) inhibitors that work by helping the body produce more insulin. Januvia was the first DPP-4 approved by the FDA and is the top-selling brand in its class. With two million prescriptions written in 2011, analysts expected Januvia to eventually produce multi-billion dollar sales numbers. Merck stands to benefit from the patent on the drug until 2022. In clinical trials Januvia proved effective in controlling blood sugar levels.
Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in patients with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Sitagliptin is in a class of medications called dipeptidyl peptidase-4 (DPP-4) inhibitors. It works by increasing the amounts of certain natural substances that lower blood sugar when it is high. Over time, people who have diabetes and high blood sugar can develop serious or life-threatening complications, including heart disease, stroke, kidney problems, nerve damage, and eye problems. Taking medication(s), making lifestyle changes (e.g., diet, exercise, quitting smoking), and regularly checking your blood sugar may help to manage your diabetes and improve your health. This therapy may also decrease your chances of having a heart attack, stroke, or other diabetes-related complications such as kidney failure, nerve damage (numb, cold legs or feet; decreased sexual ability in men and women), eye problems, including changes or loss of vision, or gum disease. Your doctor and other healthcare providers will talk to you about the best way to manage your diabetes. It is usually taken once a day with or without food. High-level prescribing trends for Metformin Hydrochloride/Sitagliptin (BNF code 0601023AD) across all GP practices in NHS England for the last five years. You can see which CCGs prescribe most of this chemical relative to its class, or learn more about this site.
Jan 29, 2014. Alogliptin is a DPP-4 inhibitor in the same class of medicines as sitagliptin. It is licensed for use in type 2 diabetes to improve glycaemic control. Dec 11, 2014. Drugs of this class include Onglyza▽ saxagliptin, Trajenta▽ linagliptin, Galvus▽ vildagliptin and Januvia sitagliptin. BNF section 6.1.2.